Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
Add filters

Journal
Year range
1.
Blood ; 138:3573, 2021.
Article in English | EMBASE | ID: covidwho-1582367

ABSTRACT

Background: Cytokine release syndrome (CRS) is a potentially serious complication of T-cell engaging immunotherapy. Effective measures are needed to reduce the rate and severity. In a multicenter Phase I/II study (NCT02500407), the CD20xCD3 bispecific antibody mosunetuzumab (Mosun) showed durable complete responses (CR) and had manageable safety in patients (pts) with late-line R/R B-NHL (Schuster et al. ASH 2019). IV administration with Cycle (C) 1 step-up dosing was an effective strategy for mitigating CRS during C1 (Bartlett et al. ASCO 2019). Fixed-dose SC administration was also a viable strategy for CRS mitigation, owing to the slower rate of Mosun absorption compared with IV (Matasar et al. ASH 2020). A combination of both strategies could further improve the CRS profile. We present safety and efficacy data from the initial cohorts investigating SC Mosun administration with C1 step-up dosing in the Phase I/II study. Methods: All pts had R/R B-NHL with ≥1 prior line of systemic therapy and ECOG PS ≤1. SC Mosun was given in 21-day cycles using two step-up dosing schedules (C1 day [D]1/C1D8/C1D15 and D1 of subsequent cycles: 5/15/45mg or 5/45/45mg). Mosun was discontinued after C8 in pts who achieved a CR, while pts with a partial response or stable disease continued Mosun for a total of 17 cycles, unless progressive disease or unacceptable toxicity occurred. Primary objectives included evaluation of safety, tolerability, and pharmacokinetics (PK). Responses were evaluated by investigator-assessment of PET/CT scans using Cheson 2007 criteria. CRS is reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019). Results: As of June 21, 2021, 74 pts had been enrolled (5/15/45mg: 38 pts;5/45/45mg: 36 pts). Median age was 67.0 years (range: 41-88). The most common NHL subtypes were DLBCL (31 pts), FL (21), transformed (tr) FL (10), and MCL (3). 70.0% of pts had Ann Arbor stage III or IV disease. Median number of prior lines of therapy was 3 (range: 1-9). 79.5% of pts were refractory to prior anti-CD20 therapy and 82.4% were refractory to their last prior therapy. Median follow-up for safety was 2.5 months (range: 0.2-7.2). No dose-limiting toxicities were observed during dose-escalation. Common all-Grade (Gr) adverse events (AEs;≥10% of pts) were injection site reaction (52.7%;Gr 1: 47.3%;Gr 2: 5.4%), CRS (24.3%), fatigue (21.6%), headache (17.6%), rash (13.5%), and pyrexia (10.8%). CRS mostly occurred in C1 and was low Gr in all pts (Gr 1: 17.6%;Gr 2: 6.8%);no Gr ≥3 CRS occurred. Gr 2 CRS occurred with a similar frequency in the 5/15/45mg and 5/45/45mg cohorts (7.9% vs 5.6% of pts, respectively). In the 5/15/45mg cohort, the 3 Gr 2 CRS events occurred after each of the C1 doses, while in the 5/45/45mg cohort, the 2 Gr 2 CRS events occurred after the first 45mg dose. Median duration of CRS was 2 days (range: 1-6) and all events resolved without sequelae. Neutropenia occurred in 12.2% of pts (Gr 2: 2.7%;Gr 3: 6.8%;Gr 4: 2.7%). Febrile neutropenia occurred in only 1 pt (Gr 3). Serious infections occurred in 3 pts (2 pneumonia, both resolved;1 COVID-19, fatal outcome). No Mosun-related Gr 5 (fatal) AEs or Mosun-related AEs leading to Mosun discontinuation occurred. The PK profile of SC Mosun was consistent with that previously reported, with high bioavailability (>85%), a slow absorption rate, and a blunted C max. IL-6 and IFN-y kinetics in plasma were similar in both SC cohorts, with modest and delayed increases observed after the initial dose, contrasting with the more marked and rapid increases observed with IV dosing, and consistent with the low frequency and severity of CRS observed. At data cut-off, 38 pts were efficacy evaluable. Responses were observed in 19 pts across all histologies, including 8/10 (80%) pts with R/R FL and 6/17 (35.3%) pts with R/R DLBCL/trFL. Conclusions: SC Mosun administration with C1 step-up dosing has a favorable safety profile in pts with late-line and highly refractory B-NHL, enabling an outpatient treatment schedule without mandatory hospitalizations. Encouragingly, the 5/45/45mg schedule had a low rate of CRS that was similar to the 5/15/45mg schedule, allowing the target dose to be reached earlier. Early response data suggest that the efficacy of Mosun is not compromised by SC dosing. Compared with IV, SC Mosun is likely to improve convenience for pts and efficiency for healthcare providers. Updated efficacy data with longer follow up and depth of response will be presented. Disclosures: Bartlett: Affimed: Research Funding;Autolus: Research Funding;Bristol-Myers Squibb: Research Funding;Celgene: Research Funding;Forty Seven: Research Funding;Janssen: Research Funding;Kite Pharma: Research Funding;Merck: Research Funding;Millennium: Research Funding;Pharmacyclics: Research Funding;Genentech, Inc./F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Research Funding;Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding;ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding;Washington University School of Medicine: Current Employment. Giri: Royal Adelaide Hospital: Current Employment. Budde: Genentech, Inc.: Consultancy;Merck, Inc: Research Funding;Amgen: Research Funding;AstraZeneca: Research Funding;Mustang Bio: Research Funding;Novartis: Consultancy;Gilead: Consultancy;Roche: Consultancy;Beigene: Consultancy. Schuster: Celgene: Consultancy, Honoraria, Research Funding;Nordic Nanovector: Consultancy;Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding;Abbvie: Consultancy, Research Funding;Acerta Pharma/AstraZeneca: Consultancy;Alimera Sciences: Consultancy;BeiGene: Consultancy;Juno Theraputics: Consultancy, Research Funding;Loxo Oncology: Consultancy;Tessa Theraputics: Consultancy;Genentech/Roche: Consultancy, Research Funding;Pharmaclyclics: Research Funding;Adaptive Biotechnologies: Research Funding;Merck: Research Funding;Incyte: Research Funding;TG Theraputics: Research Funding;DTRM: Research Funding. Assouline: Johnson&Johnson: Current equity holder in publicly-traded company;Gilead: Speakers Bureau;Amgen: Current equity holder in publicly-traded company, Research Funding;Novartis: Honoraria, Research Funding;Eli Lilly: Research Funding;Roche/Genentech: Research Funding;Jewish General Hospital, Montreal, Quebec: Current Employment;Takeda: Research Funding;BeiGene: Consultancy, Honoraria, Research Funding;F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding;AstraZeneca: Consultancy, Honoraria;AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau;Janssen: Consultancy, Honoraria;Pfizer: Consultancy, Honoraria. Matasar: Merck Sharp & Dohme: Current holder of individual stocks in a privately-held company;Juno Therapeutics: Consultancy;Janssen: Honoraria, Research Funding;Daiichi Sankyo: Consultancy;Genentech, Inc.: Consultancy, Honoraria, Research Funding;Bayer: Consultancy, Honoraria, Research Funding;Merck: Consultancy;Teva: Consultancy;TG Therapeutics: Consultancy, Honoraria;F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding;Takeda: Consultancy, Honoraria;GlaxoSmithKline: Honoraria, Research Funding;Seattle Genetics: Consultancy, Honoraria, Research Funding;Memorial Sloan Kettering Cancer Center: Current Employment;IGM Biosciences: Research Funding;Pharmacyclics: Honoraria, Research Funding;Rocket Medical: Consultancy, Research Funding;ImmunoVaccine Technologies: Consultancy, Honoraria, Research Funding. Canales: Takeda: Consultancy, Honoraria, Speakers Bureau;Incyte: Consultancy;Sandoz: Honoraria, Speakers Bureau;iQone: Honoraria;Sanofi: Consultancy;Novartis: Consultancy, Honoraria;Karyopharm: Consultancy, Honoraria;Eusa Pharma: Consultancy, Honoraria;Celgene/Bristol-Myers Squibb: Consultancy, Honoraria;Gilead/Kite: Consultancy, Honoraria;F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Speakers Bureau;Janssen: Consultancy, Honoraria, Speakers Bureau. Fay: St Vincent's Hosptial, Sydney, ustralia: Current Employment. Cheah: BMS: Consultancy, Research Funding;Abbvie: Research Funding;Janssen: Consultancy, Honoraria;MSD: Consultancy, Honoraria;Gilead: Consultancy, Honoraria;Ascentage Pharma: Consultancy, Honoraria;AstraZeneca: Consultancy, Honoraria;Lilly: Consultancy, Honoraria;TG therapeutics: Consultancy, Honoraria;Beigene: Consultancy, Honoraria;Novartis: Consultancy, Honoraria;Roche: Consultancy, Honoraria, Other: travel, Research Funding. Marlton: BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees;F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees;Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees;Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees;AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees;Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees;AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees;Queensland Health: Current Employment;Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees. Wiebking: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company;F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company. Yin: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. To: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. Li: Genentech, Inc.: Current Employment, Current holder of individual stocks in a privately-held company. Huang:F. Hoffmann-La Roche Ltd: Current Employment. Zhou: Fibrogen China: Ended employment in the past 24 months;Roche Pharma Product Development: Current Employment. Penuel: Genentech, Inc.: Current Employment, Current equity holder in publicly-traded company. O'Hear: Genentech, Inc.: Current Employment;F. Hoffmann-La Roche Ltd: Current holder of individual stocks in a privately-held company. Sehn: Novartis: Consultancy;Debiopharm: Consultancy;Genmab: Consultancy. OffLabel Disclosure: Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to engage and eliminate malignant B cells. Mosunetuzumab is an investigational agent.

2.
Chinese Journal of Pharmaceutical Biotechnology ; 28(4):395-399, 2021.
Article in Chinese | Scopus | ID: covidwho-1566895

ABSTRACT

The COVID-19 (2019 Novel Coronavirus Pneumonia) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most severe challenge facing mankind in a century. After Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019, multiple countries have experienced multiple waves of the disease. Scientific experts have been working on the characteristics of COVID-19 with the aim of finding the most appropriate way to control the virus. This phenomenon has reinforced the strong need to develop a vaccine to control the rate and spread of infection. In view of the global importance attached to COVID-19, this article mainly reviews the basic biological characteristics, sources and transmission routes of SARS-CoV-2, and provides an overview of the current clinical trials of representative new coronavirus vaccines (including inactivated vaccines, live attenuated vaccines, recombinant vector vaccines, subunit vaccines and nucleic acid vaccines) to summarize and analyze the advantages and disadvantages of various COVID-19 vaccines on the market today, and provide reference suggestions for the design and optimization of COVID-19 vaccines. © 2021, Editorial Board of Pharmaceutical Biotechnology. All right reserved.

3.
ACS Central Science ; 2021.
Article in English | Scopus | ID: covidwho-1550247

ABSTRACT

Antisense peptide nucleic acids (PNAs) have yet to translate to the clinic because of poor cellular uptake, limited solubility, and rapid elimination. Cell-penetrating peptides (CPPs) covalently attached to PNAs may facilitate clinical development by improving uptake into cells. We report an efficient technology that utilizes a fully automated fast-flow instrument to manufacture CPP-conjugated PNAs (PPNAs) in a single shot. The machine is rapid, with each amide bond being formed in 10 s. Anti-IVS2-654 PPNA synthesized with this instrument presented threefold activity compared to transfected PNA in a splice-correction assay. We demonstrated the utility of this approach by chemically synthesizing eight anti-SARS-CoV-2 PPNAs in 1 day. A PPNA targeting the 5′ untranslated region of SARS-CoV-2 genomic RNA reduced the viral titer by over 95% in a live virus infection assay (IC50 = 0.8 μM). Our technology can deliver PPNA candidates to further investigate their potential as antiviral agents. ©

4.
Preprint in English | PUBMED | ID: ppcovidwho-293352

ABSTRACT

The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or generate lists of differentially expressed genes between control and SARS-CoV-2-infected samples. Using a rank-based pattern matching strategy based on the Kolmogorov-Smirnov Statistic, the signatures were queried against drug profiles from Connectivity Map (CMap). We validated sixteen of our top predicted hits in live SARS-CoV-2 antiviral assays in either Calu-3 or 293T-ACE2 cells. Validation experiments in human cell lines showed that 11 of the 16 compounds tested to date (including clofazimine, haloperidol and others) had measurable antiviral activity against SARS-CoV-2. These initial results are encouraging as we continue to work towards a further analysis of these predicted drugs as potential therapeutics for the treatment of COVID-19.

5.
Future Virology ; 16(7):447-450, 2021.
Article in English | EMBASE | ID: covidwho-1526742

ABSTRACT

Tweetable To adapt to human host environment, synonymous mutations in SARS-CoV-2 are shaped by tRNA selection, energy cost and RNA structure.

6.
Kexue Tongbao/Chinese Science Bulletin ; 66(31):3925-3931, 2021.
Article in Chinese | Scopus | ID: covidwho-1523391

ABSTRACT

Left unmitigated, climate change poses a catastrophic risk to human health, demanding an urgent and concerted response from every country. The 2015 Lancet Commission on Health and Climate Change and The Lancet Countdown: Tracking Progress on Health and Climate Change have been initiated to map out the impacts of climate change and the necessary policy responses. To meet these challenges, Tsinghua University, partnering with the University College London and 17 Chinese and international institutions, has prepared the Chinese Lancet Countdown report, which has a national focus and builds on the work of the global Lancet Countdown: Tracking Progress on Health and Climate Change. Drawing on international methodologies and frameworks, this report aims to deepen the understanding of the links between public health and climate change at the national level and track them with 23 indicators. This work is part of the Lancet's Countdown broader efforts to develop regional expertise on this topic, and coincides with the launch of the Lancet Countdown Regional Centre in Asia, based at Tsinghua University. The data and results of this report are presented at the provincial level, where possible, to facilitate targeted response strategies for local decision-makers. Based on the data and findings of the 2020 Chinese Lancet Countdown report, five recommendations are proposed to key stakeholders in health and climate change in China: (1) Enhance inter-departmental cooperation. Climate change is a challenge that demands an integrated response from all sectors, urgently requiring substantial inter-departmental cooperation among health, environment, energy, economic, financial, and education authorities. (2) Strengthen health emergency preparedness. Knowledge and findings on current and future climate-related health threats still lack the required attention and should be fully integrated into the emergency preparedness and response system. (3) Support research and raise awareness. Additional financial support should be allocated to health and climate change research in China to enhance health system adaptation, mitigation measures, and their health benefits. At the same time, media and academia should be fully motivated to raise the public and politicians' awareness of this topic. (4) Increase climate change mitigation. Speeding up the phasing out of coal is necessary to be consistent with China's pledge to be carbon neutral by 2060 and to continue to reduce air pollution. Fossil fuel subsidies must also be phased out. (5) Ensure the recovery from COVID-19 to protect health now and in the future. China's efforts to recover from COVID-19 will shape public health for years to come. Climate change should be a priority in these interventions. © 2021, Science Press. All right reserved.

7.
Research and Practice in Thrombosis and Haemostasis ; 5(SUPPL 2), 2021.
Article in English | EMBASE | ID: covidwho-1509046

ABSTRACT

Background : Patients with hemophilia require regular assessments and physical examinations. The COVID-19 pandemic has resulted in the rapid adoption of telemedicine to enable virtual consultations and reduce hospital visits. However, the process of virtual consultations is new to many hemophilia clinics. A better understanding of best practices in telemedicine is important to ensure optimal quality of care for patients with hemophilia. Aims : To summarize the current literature on the use of direct-toconsumer telemedicine for patients with hemophilia and to describe the effectiveness and potential limitations of the technology and methods used. Methods : A comprehensive search was conducted in MEDLINE and EMBASE databases using the terms “hemophilia” AND “telemedicine” and their concept synonyms. There were no time or language restrictions. Title, abstracts, and full texts were screened. Included articles involved telemedicine interventions to facilitate clinical services directly between patients and providers without the use of third-party personnel. The primary outcome was the satisfaction of providers and patients. Secondary outcomes included economic considerations and clinical outcomes. Data were extracted based on study-specific, patient-specific, intervention-specific, and outcome-specific data. Results : Of the 925 articles screened, 6 articles were identified and summarized (Figure 1). Three articles described telemedicine within the context of COVID-19. Technologies used included telephone calls, videoconferencing, text messaging, and email. All studies involved a multidisciplinary team. Telemedicine in hemophilia care was found to positively impact the patient experience. Providers were satisfied with telemedicine. Telemedicine was economically beneficial and positively impacted patient outcomes. However, none of the articles reported on how telemedicine was specifically used to perform assessments during the virtual consultation process. Conclusions : The positive reception of telemedicine by patients and providers combined with the limited information available on methods of virtual assessments necessitates the development of a standard telemedicine guideline that can help providers learn how to best incorporate telemedicine to improve quality of care.

8.
American Journal of Cancer Research ; 11(10):4994-5005, 2021.
Article in English | EMBASE | ID: covidwho-1498709

ABSTRACT

SARS-CoV-2 exploits the host cellular machinery for virus replication leading to the acute syndrome of coronavirus disease 2019 (COVID-19). Growing evidence suggests SARS-CoV-2 also exacerbates many chronic diseases, including cancers. As mutations on the spike protein (S) emerged as dominant variants that reduce vaccine efficacy, little is known about the relation between SARS-CoV-2 virus variants and cancers. Compared to the SARS-CoV-2 wild-type, the Gamma variant contains two additional NXT/S glycosylation motifs on the S protein. The hyperglycosylated S of Gamma variant is more stable, resulting in more significant epithelial-mesenchymal transition (EMT) potential. SARS-CoV-2 infection promoted NF-κB signaling activation and p65 nuclear translocation, inducing Snail expression. Pharmacologic inhibition of NF-κB activity by nature food compound, I3C suppressed viral replication and Gamma variant-mediated breast cancer metastasis, indicating that NF-κB inhibition can reduce chronic disease in COVID-19 patients. Our study revealed that the Gamma variant of SARS-CoV-2 activates NF-κB and, in turn, triggers the pro-survival function for cancer progression.

9.
Journal of Spinal Cord Medicine ; 44(5):819, 2021.
Article in English | EMBASE | ID: covidwho-1493425

ABSTRACT

Background: Little is known about how the COVID-19 restrictions have affected people with SCI and whether they will be vaccinated. Objective: Our purpose is twofold: (1) identify the portion of people planning on taking the COVID vaccine, and (2) how their health, participation, and quality-of-life changed after the beginning of the pandemic. We use a natural experiment, comparing outcomes just prior to the start of the COVID-19 pandemic, and again 12 months later. Design: Prospective cohort study Methods: Participants were identified through a population-based registry. 333 participants completed selfreport assessments (SRA) between December 17, 2019, and March 17, 2020. 62 returned follow-up materials approximately 12 months later. Data collection is currently in progress, with a projected total response of approximately 150-175 participants. The SRA measures a broad spectrum of outcomes and is being collected by mail and online along with a COVID -19 supplement. Results Observed: The preliminary analysis of the supplement indicates that 41.9% had been tested. Only 65.6% of the participants were planning on taking the vaccine, with the concern being side effects (47.5%). Well over half self-reported being adversely affected by COVID-19 restrictions, particularly participation, and just under 25% of those requiring personal assistance relied heavily on family members. Longitudinal comparisons of the SRA require completion of data collection and will be presented. Conclusions: COVID-19 restrictions have a significant impact people with SCI and a substantial portion are not planning on being vaccinated due to concerns about side effects. Longitudinal comparisons will identify actual changes in outcomes.

10.
IEEE Transactions on Computational Social Systems ; 2021.
Article in English | Scopus | ID: covidwho-1483778

ABSTRACT

Corona Virus Disease 2019 (COVID-19), due to its extremely high infectivity, has been spreading rapidly around the world and bringing huge influence to socioeconomic development and people's daily life. Taking for example the virus transmission that may occur after college students return to school, we analyze the quantitative influence of the key factors on the virus spread, including crowd density and self-protection. One Campus Virus Infection and Control Simulation (CVICS) model of the novel coronavirus is proposed in this article, fully considering the characteristics of repeated contact and strong mobility of crowd in the closed environment. Specifically, we build an agent-based infection model, introduce the mean field theory to calculate the probability of virus transmission, and microsimulate the daily prevalence of infection among individuals. The experimental results show that the proposed model in this article efficiently simulates how the virus spreads in the dense crowd in frequent contact under a closed environment. Furthermore, preventive and control measures, such as self-protection, crowd decentralization, and isolation during the epidemic, can effectively delay the arrival of infection peak, reduce the prevalence, and, finally, lower the risk of COVID-19 transmission after the students return to school. IEEE

11.
12.
Chinese Journal of New Drugs ; 30(19):1775-1782, 2021.
Article in Chinese | EMBASE | ID: covidwho-1473137

ABSTRACT

Objective: To compare the correlation between the results of SARS-CoV-2 neutralizing antibody colloidal gold test cards prepared by two different principles and the SARS-CoV-2 pseudovirus neutralization experiment, and to evaluate the feasibility of the neutralizing antibody colloidal gold test card for the SARS-CoV-2 neutralizing antibody detection in different populations. Methods: Two kinds of SARS-CoV-2 neutralizing antibody colloidal gold test cards using double antigen sandwich method (manufacturer A) and competitive blocking method (manufacturers B) were used to detect the samples with SARS-CoV-2 neutralizing antibody titers. Detection sensitivity and the correlation between the two methods and the neutralization experiment were compared. The intravenous human immunoglobulin and specific immunoglobulin prepared before the outbreak of COVID-19 epidemic were detected to investigate the specificity of the eligible test card. In order to determine whether there is a hook effect, individual immunized plasma samples of high ELISA titers were tested with series of dilutions and original dilution. Single post-immunized plasma samples were detected with different ELISA titers, the positive rates were determined and the color changes were observed. Single post-immunized plasma samples were screened in the low-dilution area of ELISA according to chromaticity of 120NT50 and 300NT50 on the colorimetric card to prepare pooled plasma. The results were compared with the currently used indirect ELISA method. Results: The detection limits of manufacturers A and B for the first-generation NIBSC international standard 20/136 (anti-SARS-CoV-2 human immunoglobulin international standard) were 0.612 5 and 5 IU•mL-1, respectively. The results of different titers of pooled plasma (both of post-immunization with SARS-CoV-2 vaccine and COVID-19 convalescence plasma) have a good correlation with the neutralizing antibody titer. The post-immunization plasma with high ELISA dilutions (above 10 000) did not show hook effect. The positive rate of individual plasma of different ELISA dilution levels reached 100% when the dilution was above 160, and the uniformity of the chromaticity was higher when the dilution level was above 640. The overall chromaticity became darker as the ELISA dilution increased. The chromaticities of Ppool 120NT50 and Ppool 300NT50 screened according to the colorimetric chart were close to the neutralizing antibody titers. Conclusion: The correlation between the results of the manufacturer A neutralizing antibody test card using the dual antigen sandwich method to detect SARS-CoV-2 neutralizing antibody in convalescent plasma and post-immunization plasma and the titer of the pseudovirus neutralization experiment is better than that of the manufacturer B product using the competitive inhibition method and indirect ELISA. And the color brightness of the detection line is positively correlated with the level of neutralizing antibody, which can be used for preliminary screening of neutralizing antibody in different populations.

13.
Chest ; 160(4):A2140, 2021.
Article in English | EMBASE | ID: covidwho-1466196

ABSTRACT

TOPIC: Pulmonary Manifestations of Systemic Disease TYPE: Medical Student/Resident Case Reports INTRODUCTION: Babesiosis is a tick-borne illness caused by B. microti and other species and transmitted by the Ixodes tick. Acute respiratory distress syndrome (ARDS) can be a manifestation of babesiosis. CASE PRESENTATION: A 69 year old female with the past medical history of HTN, HLD and hypothyroidism who presented to hospital for 1 week of intermittent fever and generalized body aches. Patient denied any tick bites. She started to have intermittent fever around 40°C, nonproductive cough and generalized body aches, associated with night sweats, nausea, diarrhea. She took 1000mg Tylenol every 4 hours for fever and body aches for 1 week without improvement.Upon admission laboratory values were significant for hemolytic anemia (Hgb 9.4 g/dL, reticulocyte count 1.2%, LDH 4896 U/L, haptoglobin < 8mg/dL, total bilirubin 2.3 mg/dL), thrombocytopenia (platelet 38× 103/mm3) and leukopenia (WBC 2.7× 103/mm3), significantly elevated acetaminophen level (22.6), transaminitis (ALT 365 IU/L, AST 579 IU/L) and elevated INR (1.4). Blood parasite smear was positive for blood parasites (Malaria/Babesia: 9.6% RBC infected). Babesia Microti DNA RT-PCR was positive, Babesia Microti Ab (IgM) ≥ 1:320, Babesia Microti Ab (IgG) was 1:512, E. Chaffeensis Ab Ig G <1:64, E. Chaffeensis Ab Ig M <1:20, Lyme Ab Scr-Q <0.90. HIV and blood culture was negative. SARS-CoV-2 RNA was negative.Patient was admitted and received Acetylcysteine for acetaminophen toxicity, atovaquone, azithromycin, doxycycline for Babesia and borreliosis coverage. On day 2 of admission, acetaminophen level decreased to less than 10, transaminitis slowly improved. But patient developed shortness of breath, cough and hypoxia. Concerning severe babesiosis induced ARDS, chest CT angiogram was ordered and showed no evidence of pulmonary embolism but mild pulmonary interstitial edema. 2D Echo showed normal left ventricular systolic function and mild diastolic dysfunction. Patient received IV Lasix, symptoms improved and the CXR on day 6 showed pulmonary edema resolved.In the following days, patient continued to receive treatment for babesiosis, blood parasitemia cleared but Hgb decreased to 6.7 g/dL, patient received transfusion and Hgb level remained 7.9 g/dL on the day of discharge. 5 days after discharge, patient's Hgb level increased to 9 g/dL. 1 month after discharge, Hgb level increased to 12g/dL and transaminase level returned to normal. DISCUSSION: ARDS is a life-threatening condition characterized by severe hypoxemia due to pulmonary gas exchange failure. Though uncommon, tick-borne diseases could present with ARDS. Moreover, acetaminophen toxicity has also been linked to acute lung injury, making the correct diagnosis challenging. Early recognition and intervention led to a favorable outcome. CONCLUSIONS: ARDS can be an early onset manifestation after initiation of treatment for babesiosis and usually resolves with supportive treatment. REFERENCE #1: Autoimmune hemolytic anemia associated with babesiosis.Roshni Narurkar, Aleksandra Mamorska-Dyga, John C. Nelson and Delong Liu.Biomarker Research (2017) 5:14. REFERENCE #2: Yousef Nassar, Seth Richter. Babesiosis Presenting as Acute Liver Failure. Case Rep Gastroenterol 2017;11:769–773. REFERENCE #3: Boustani MR, Lepore TJ, Gelfand JA, Lazarus DS. Acute respiratory failure in patients treated for babesiosis. Am J Respir Crit Care Med. 1994 Jun;149(6):1689-91. doi: 10.1164/ajrccm.149.6.8004331.PMID: 8004331 Review. DISCLOSURES: No relevant relationships by Heather Bernstein, source=Web Response No relevant relationships by ALKA FARMER, source=Web Response No relevant relationships by CUIPING LI, source=Web Response No relevant relationships by Vinay Nakhate, source=Admin input No relevant relationships by kiritkumar parmar, source=Web Response No relevant relationships by Lin Zheng, source=Web Response

14.
Latin American Journal of Pharmacy ; 40(10):2527-2531, 2021.
Article in English | EMBASE | ID: covidwho-1464464

ABSTRACT

In the present study, a new Co(II)-Schiff base complex, [Co(HL)2Cl2] (1), [Schiff base (HL) = 2-(2-methoxybenzylideneamino)phenol] has been successfully prepared by reaction of Co(II) chloride hexahydrate with the Schiff base ligand HL in a mixed solvent of aqueous-methanolic solution via a slow evaporation synthesis method. For the treatment of SARS-COV-2 induced acute lung injury, the ELISA detection kit was performed in the research to measure the content of inflammatory cytokines TNF-α and IFN-γ released into the alveolar lavage fluid. In addition to this, the activation levels of the prolyl carboxypeptidase in the alveolar epithelial cells were determined with real time RT-PCR.

15.
Antimicrobial Resistance and Infection Control ; 10(SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1448437

ABSTRACT

Introduction: This study is the first to focus on the different respiratory support modes and outcomes of critically ill patients with COVID- 19 in Wuhan. The cohort study design is persuasive. The number of studies retrieved is limited in patients with MDRO coinfected with COVID-19. This study only selected critically ill patients with COVID-19 in Leishenshan Hospital. Objectives: We aimed to describe the clinical characteristics and outcomes of five different modes of respiratory support among critically ill patients with coronavirus disease 2019 (COVID-19). Methods: This was a hospital-based, retrospective cohort study which setting on Leishenshan hospital in Wuhan, central China. Patients with COVID-19 admitted to the ICU of Leishenshan Hospital from February 8, 2020 to April 18, 2020 were recruited. The outcome was living status and survival time. Results: Thirty-five patients died among 114 hospitalization patients (mortality rate, 30.7%), and 56 patients (49.12%) used mechanical ventilation. The mean survival time (days) of patients without respiratory support, noninvasive positive-pressure ventilation (NIPPV), endotracheal intubation, tracheotomy, or endotracheal intubation before and after tracheotomy (EI + T) was 15, 34, 32, 12.5, and 6, respectively (p < 0.000). Eighteen (15.79%) patients were co-infected with MDROs, primarily in the EI + T group (83.33%). The mortality risk of patients treated with NIPPV and EI + T was 0.20 and 0.21 times higher than that of patients without any respiratory support (95% confidence interval [CI] = 0.002-0.203;95% CI = 0.002-0.218). The mode of respiratory support was an independent factor affecting the survival of ICU patients with COVID-19. Conclusion: Mortality risk in patients with NIPPV and EI + T was lower than in those without any respiratory support. Timely and correct respiratory support mode is the key to reducing the death of critically ill patients with COVID-19.

16.
Preprint in English | MEDLINE | ID: ppcovidwho-290972

ABSTRACT

Purpose There is limited information on how the COVID-19 pandemic has changed health behaviors among cancer patients. We examined the impact of the pandemic on changes in exercise behaviors and identified characteristics associated with these changes among cancer patients. Methods Cancer patients (n <b>=</b> 1,361) completed a survey from August-September 2020 to assess COVID-19 pandemic-related changes in health behaviors and psychosocial factors. Patients were categorized into 3 groups: exercising less, exercising did not change, and exercising more. Patient characteristics were compared by exercise groups. Results One-third of the patients reported a decreased amount of regular exercise, while 11% reported exercising more during the pandemic. Patients who exercised less were more likely to be unemployed/retired, undergoing active treatment, and had increased pandemic-related alcohol consumption and psychosocial stressors such as loneliness and financial stress (all p < 0.05). In contrast, patients who exercised more were younger, female, full-time employed, did not consume alcohol, and had good health status and more social interactions (all p < 0.05). Patients who were living in rural areas and did not experience changes in daily life, were also more likely not to experience changes in exercise habits (all p < 0.05). Conclusion Our results indicate that a significant proportion of cancer patients experienced changes in exercise habits during the first 6 months of the COVID-19 pandemic. Age, sex, employment status, health status, alcohol consumption, and psychosocial factors were associated with changes in exercise behaviors. Providers should monitor for changes in health behaviors, such as exercise, because of their importance in improving cancer survivorship.

18.
IEEE Symposium Series on Computational Intelligence (IEEE SSCI) ; : 2178-2185, 2020.
Article in English | Web of Science | ID: covidwho-1431470

ABSTRACT

In this study, we conduct a network analysis with centrality measures, using historical daily close prices of top 120 cryptocurrencies between 2013 and 2020, to study and understand the dynamic evolution and characteristics of the cryptocurrency market. Our study has two primary findings: (1) the overall cross-return correlation among the cryptocurrencies is weakening from 2013 to 2016 and then strengthening thereafter;(2) cryptocurrencies that are primarily used for transaction payment, notably BTC, dominate the market until mid-2016, followed by those developed for applications using blockchain as the underlying technology, particularly data storage and recording such as MAID and FCT, between mid-2016 and mid-2017. Since then, ETH, alongside with its strongly correlated cryptocurrencies have replaced BTC to become the benchmark cryptocurrencies. Furthermore, during COVID-19, QTUM and BNB have intermittently replaced ETH to take the leading positions due to their active community engagement during the pandemic.

19.
J Eur Acad Dermatol Venereol ; 2021 Sep 21.
Article in English | MEDLINE | ID: covidwho-1429889
20.
American Journal of Respiratory and Critical Care Medicine ; 203(9):2, 2021.
Article in English | Web of Science | ID: covidwho-1407282
SELECTION OF CITATIONS
SEARCH DETAIL
...